Thursday Mar 6
Opening Statements Begin in Billion Dollar Actos Trial
Actos, released in 1999, was marketed as a drug to treat Type II diabetes by helping sensitize cells to insulin, thus assisting in blood sugar control.
Low-Level Usage Of Takeda Pharmaceutical Co. Ltd.'s Actos May Still...
Study Says Low-Level Actos Users May Still Face Bladder Cancer Risk, According to Cancer Monthly Raleigh, NC February 26, 2014 -- A new article published in the Journal of Korean Medical Science and reported by Cancer Monthly finds that diabetics who have been treated with pioglitazone for more than 6 months may still face a higher risk of bladder ... (more)